Industry Gets Say At DIA As New China Drug Law In The Works
This article was originally published in PharmAsia News
A marketing authorization holder system, faster and strict timeframes for investigative new drug approval, and stricter monitoring of off-label drug use were the top topics at a special discussion of China’s top regulators, legal experts and industry executives.
You may also be interested in...
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.